目次

Table of Content

1. Introduction To CD276 Targeted Therapy

2. Clinical Approaches To Target CD276
2.1 Monoclonal Antibodies Against CD276
2.2 Cell Therapy Against CD276
2.3 Multispecific Antibodies
2.4 Small Molecule Inhibitors
2.5 Antibody Drug Conjugates

3. Global CD276 Targeted Therapy Market Outlook
3.1 Current Market Trends and Developments
3.2 Future Market Opportunities

4. Global CD276 Antibody Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Phase
4.5 By Priority Development and Orphan Status

5. Global CD276 Antibody Clinical Trials By Company, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
5.6 Phase-III
5.7 Preregistration

6. Understanding CD276 In Cancer
6.1 Multifaceted Role Of CD276 In Cancer
6.2 Research Innovations and Clinical Progress

7. Targeting CD276 As A Strategy For Cancer Treatment
7.1 As Targeted Therapy
7.2 As Monotherapy
7.3 As Combination Therapy

8. Role Of CD276 Beyond Cancer
8.1 Autoimmune and Inflammatory Diseases
8.2 Microbial Infections
8.3 Metabolic Diseases

9. Global CD276 Inhibitors Market Dynamics
9.1 Drivers and Opportunities
9.2 Challenges and Restraints

10. Competitive Landscape
10.1 Aleta Biotherapeutics
10.2 Beijing Biocytogen
10.3 Beijing Mabworks Biotech
10.4 BoYuan RunSheng Pharma
10.5 Daiichi Sankyo Company
10.6 Elpis Biopharmaceuticals
10.7 Fate Therapeutics
10.8 Innate Pharma
10.9 Invenra
10.10 MacroGenics
10.11 Minghui Pharmaceutical (Shanghai)
10.12 Nanjing Kati Medical Technology
10.13 PersonGen Biotherapeutics
10.14 Radiopharm Ventures
10.15 Shanghai Hansoh Biomedical
10.16 Shattuck Labs
10.17 TrueBinding
10.18 TC BioPharm

List of Figures
Figure 1-1: CD276 - Mechanism Of Immune Suppression
Figure 1-2: CD276: Impact On Immune Cells
Figure 1-3: CD276 - Role In Non-Oncological Diseases
Figure 2-1: CD276 - Targeting With Monoclonal Antibodies
Figure 2-2: Challenges In Developing CD276 Blocking mAbs
Figure 2-3: CD276-Targeted CAR-T Cells - Mechanism Of Action
Figure 2-4: Targeting CD276 - CAR-T Cell Design
Figure 2-5: Gene Editing Strategies To Improve CD276 CAR-T Cell Persistence
Figure 2-6: Bispecific Antibodies Targeting CD276
Figure 2-7: Technical University of Darmstadt - Trispecific Antibody Targeting CD276
Figure 2-8: Small Molecule Inhibitors Targeting CD276 - Mechanism Of Action
Figure 2-9: Small Molecule Inhibitor - Design and Development Process
Figure 2-10: CD276 Antibody Drug Conjugate - Schematic
Figure 2-11: CD276-Targeted Antibody Drug Conjugates - Mechanism Of Action
Figure 3-1: CD276 Targeted Therapy Market - Future Opportunities
Figure 4-1: Global - Number Of CD276 Antibodies In Clinical Pipeline By Company, 2025 Till 2026
Figure 4-2: Global - Number Of CD276 Antibodies In Clinical Pipeline By Country, 2025 Till 2026
Figure 4-3: Global - Number Of CD276 Antibodies In Clinical Pipeline By Indication, 2025 Till 2026
Figure 4-4: Global - CD276 Antibody Clinical Pipeline By Phase, 2025 Till 2026
Figure 4-5: Global - CD276 Antibody Designation By Priority Development and Orphan Status, 2025 Till 2026
Figure 6-1: Cancer - CD276 Mediated Signaling Pathways
Figure 6-2: IDeate-Lung01 Phase 2 (NCT05280470) Study - Initiation and Completion Year
Figure 6-3: CP-MGC026-01 Phase 1 (NCT06242470) Study - Initiation and Completion Year
Figure 6-4: BrainChild-03 Phase 1 (NCT04185038) Study - Initiation and Completion Year
Figure 6-5: DB-1311-O-1001 Phase 1/2 (NCT05914116) Study - Initiation and Completion Year
Figure 6-6: BNT324-01 Phase 2 (NCT06892548) Study - Initiation and Completion Year
Figure 6-7: DB-1311-201 Phase 2 (NCT06953089) Study - Initiation and Completion Year
Figure 6-8: BetaBart-US-101 Phase 1/2 (NCT07189871) Study - Initiation and Completion Year
Figure 8-1: Autoimmune and Inflammatory Diseases - Dual Immunomodulatory Role Of CD276
Figure 8-2: Type 1 Diabetes - CD276 As Biomarker For Early Detection
Figure 8-3: Ankylosing Spondylitis - Epigenetic Regulation Of CD276
Figure 8-4: Infection - Dual Role Of CD276
Figure 8-5: Infectious Diseases - Challenges In CD276-Targeted Therapies
Figure 8-6: CD276 - Role In Adipose Tissue and Metabolic Homeostasis
Figure 9-1: Global CD276 Inhibitors Market - Drivers and Opportunities
Figure 9-2: Global CD276 Inhibitors Market - Challenges and Strategic Solutions